Skip to main content
. 2024 Oct 8;32(1):132–143. doi: 10.1007/s12282-024-01640-z

Table 1.

Baseline demographics and disease characteristics

All patients Patients with PIK3CA/AKT1/PTEN-altered tumors
Japan subgroup Global CAPItello-291 population Japan subgroup Global CAPItello-291 population
Capivasertib–fulvestrant (n = 37) Placebo–fulvestrant (n = 41) Capivasertib–fulvestrant (n = 355) Placebo–fulvestrant (n = 353) Capivasertib–fulvestrant (n = 19) Placebo–fulvestrant (n = 19) Capivasertib–fulvestrant (n = 155) Placebo–fulvestrant (n = 134)
Demographics
Median age (range), years 61 (42–84) 61 (37–83) 59 (26–84) 58 (26–90) 61 (48–84) 62 (39–80) 58 (36–84) 60 (34–90)
Female sex, n (%) 37 (100) 41 (100) 352 (99.2) 349 (98.9) 19 (100) 19 (100) 153 (98.7) 134 (100)
Postmenopausal, n (%) 29 (78.4) 29 (70.7) 287 (80.8) 260 (73.7) 15 (78.9) 14 (73.7) 130 (83.9) 105 (78.4)
Asian, n (%) 37 (100) 41 (100) 95 (26.8) 94 (26.6) 19 (100) 19 (100) 48 (31.0) 35 (26.1)
ECOG performance status score, n (%)
0 35 (94.6) 35 (85.4) 224 (63.1) 241 (68.3) 19 (100) 18 (94.7) 93 (60.0) 97 (72.4)
1 2 (5.4) 6 (14.6) 131 (36.9) 111 (31.4) 0 1 (5.3) 62 (40.0) 36 (26.9)
2 0 0 0 1 (0.3) 0 0 0 1 (0.7)
Disease characteristics
Liver metastasis,a n (%) 11 (29.7) 13 (31.8) 156 (43.9) 150 (42.5) 4 (21.1) 6 (31.6) 70 (45.2) 53 (39.6)
Number of previous therapies for advanced breast cancer, n (%)
0 11 (29.7) 16 (39.0) 37 (10.4) 52 (14.7) 5 (26.3) 7 (36.8) 12 (7.7) 20 (14.9)
1 17 (45.9) 16 (39.0) 235 (66.2) 208 (58.9) 10 (52.6) 6 (31.6) 107 (69.0) 79 (59.0)
2 8 (21.6) 7 (17.1) 73 (20.6) 77 (21.8) 4 (21.1) 4 (21.1) 31 (20.0) 29 (21.6)
3 1 (2.7) 2 (4.9) 10 (2.8) 16 (4.5) 0 2 (10.5) 5 (3.2) 6 (4.5)
Hormone-receptor status,b n (%)
ER-positive, PgR-positive 30 (81.1) 33 (80.5) 255 (71.8) 246 (69.7) 16 (84.2) 14 (73.7) 116 (74.8) 101 (75.4)
ER-positive, PgR-negative 7 (18.9) 8 (19.5) 94 (26.5) 103 (29.2) 3 (15.8) 5 (26.3) 35 (22.6) 31 (23.1)
ER-positive, with unknown PgR status 0 0 5 (1.4) 4 (1.1) 0 0 4 (2.6) 2 (1.5)
Endocrine status,c n (%)
Primary resistance 15 (40.5) 14 (34.1) 127 (35.8) 135 (38.2) 10 (52.6) 6 (31.6) 60 (38.7) 55 (41.0)
Secondary resistance 22 (59.5) 27 (65.9) 228 (64.2) 218 (61.8) 9 (47.4) 13 (68.4) 95 (61.3) 79 (59.0)
Number of previous endocrine therapies for advanced breast cancer, n (%)
0 11 (29.7) 16 (39.0) 39 (11.0) 54 (15.3) 5 (26.3) 7 (36.8) 13 (8.4) 20 (14.9)
1 19 (51.4) 18 (43.9) 287 (80.8) 252 (71.4) 11 (57.9) 8 (42.1) 131 (84.5) 96 (71.6)
2 7 (18.9) 7 (17.1) 29 (8.2) 47 (13.3) 3 (15.8) 4 (21.1) 11 (7.1) 18 (13.4)
Previous CDK4/6 inhibitor, n (%)
As neoadjuvant or adjuvant therapy 0 0 2 (0.6) 5 (1.4) 0 0 0 2 (1.5)
As therapy for advanced breast cancer 5 (13.5) 8 (19.5) 245 (69.0) 244 (69.1) 4 (21.1) 3 (15.8) 113 (72.9) 91 (67.9)
Previous chemotherapy, n (%)
As neoadjuvant or adjuvant therapy 15 (40.5) 19 (46.3) 180 (50.7) 170 (48.2) 6 (31.6) 8 (42.1) 79 (51.0) 67 (50.0)
As therapy for advanced breast cancer 3 (8.1) 4 (9.8) 65 (18.3) 64 (18.1) 1 (5.3) 4 (21.1) 30 (19.4) 23 (17.2)

AKT1 Akt serine/threonine kinase 1, CDK 4/6 cyclin-dependent kinases 4/6, ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PIK3CA catalytic subunit of phosphatidylinositol-3-kinase, PgR progesterone receptor, PTEN phosphatase and tensin homolog

aBaseline stratification factor

bOne patient in the global CAPItello-291 population treated with capivasertib–fulvestrant was ER-negative

cPrimary and secondary resistance were defined using the 4th European School of Oncology-European Society for Medical Oncology International Consensus Guidelines for advanced breast cancer